• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Ticagrelor reversal agent provides immediate and sustained effect

byDayton McMillan
May 9, 2019
in Cardiology, Chronic Disease, Emergency, Gastroenterology, Surgery
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. A monoclonal antibody fragment to ticagrelor, PB2452, increased platelet function significantly in healthy patients given the oral P2Y12 inhibitor ticagrelor.

2. Adverse effects were mainly limited to the infusion site, with limited systemic events.

Evidence Rating Level: 1 (Excellent)      

Study Rundown: Antiplatelet therapy is used extensively for prevention of cardiovascular occlusive events. Many patients receive dual-antiplatelet therapy with both aspirin and a P2Y12 inhibitor. Despite stoppage of P2Y12 inhibitors, patients can be at increased bleeding risk for several days after their last dose. This puts urgent surgical or invasive procedures at increased risk for excessive bleeding or can cause delay in surgery to allow the drug effect to wear off as there is no approval or effective reversal agent. PB2452 is a monoclonal antibody fragment developed as an antiplatelet agent for ticagrelor. This phase 1 study evaluated the safety and effect of PB2452. After PB2452 infusion, volunteers treated with ticagrelor had significantly increased platelet function, with maximal effect seen at 30 minutes following infusion. Following an extended PB2452 infusion, volunteers had platelet function return for up to 20 hours. Approximately one-third of participants receiving PB2452 experienced an adverse event, with most being proximal to the infusion site.

The results of this phase 1 study suggest that PB2452 can be a clinically useful ticagrelor reversal agent. Its strengths include testing of a first-in-class drug candidate and complete evaluation of safety outcomes. Its main limitation as a phase 1 study was the limited number of participants and narrow evaluation of drug efficacy.

Click to read the study, published today in NEJM

Relevant Reading: Novel antibody-based reversal agent for ticagrelor

RELATED REPORTS

CYP2C19 loss-of-function carriers have modest benefit from ticagrelor and aspirin following cerebrovascular event: CHANCE-2 Trial

Treatment with clopidogrel with aspirin or ticagrelor with aspirin produces similar risk reduction of stroke recurrence or death

Abbreviated dual antiplatelet therapy could improve outcome after percutaneous coronary intervention

In-Depth [randomized controlled trial]: This phase 1, single-center, double-blind, randomized controlled trial enrolled healthy volunteers between 18 and 50 years old during 2018. Participants were pretreated with ticagrelor and then assigned in a 3:1 ratio to receive either PB2452 (n=48), with 21 volunteers receiving the highest dose (18g), or placebo (n=16). Adverse events occurred in 35% of those receiving PB2452 (17/48), with 27 adverse events being reported in the group. Of the 16 volunteers receiving placebo, 2 (12%) reported an adverse event. No adverse events necessitated drug discontinuation or hospitalization. Ticagrelor was given 48 hours before either PB2452 or placebo treatment, and at 48 hours platelet aggregation was suppressed by 80-85%. After 30 minutes of PB2452 infusion of either 3g or 9g, maximal effect was seen immediately after the infusion ended and reversal effect lasted from 1 to 2 hours. When administered a 6g PB2452 bolus, reversal effect was seen at 5 minutes. When infusions were given over 12 to 16 hours, the PB2452 reversal effect lasted up to 20 hours. Multiple laboratory measurements were used to assess platelet activity and reversal agent effect. Antibodies to PB2452 were detected in 21 of 48 participants (44%) within 28 days of drug administration.

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc

Tags: dual anti-platelet therapy (DAPT)monocloncal antibodyPB2452Ticagrelor
Previous Post

Life satisfaction scores similar for healthy and chronically ill children  

Next Post

The PRISM trial: Progesterone therapy does not alter birth outcomes in women with early pregnancy bleeding

RelatedReports

Intensive rehabilitation not superior to traditional therapy for arm function after stroke
Chronic Disease

CYP2C19 loss-of-function carriers have modest benefit from ticagrelor and aspirin following cerebrovascular event: CHANCE-2 Trial

June 23, 2022
Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial
Emergency

Treatment with clopidogrel with aspirin or ticagrelor with aspirin produces similar risk reduction of stroke recurrence or death

December 9, 2021
Drug-coated balloons are noninferior to drug-eluting stents for treatment of small vessel coronary artery disease
Cardiology

Abbreviated dual antiplatelet therapy could improve outcome after percutaneous coronary intervention

November 9, 2021
Colchicine may lower the risk of cardiovascular events in patients with coronary disease
Cardiology

De-escalation with clopidogrel may reduce bleeding events in patients with recent percutaneous coronary intervention

October 19, 2021
Next Post
Paternal factors associated with short interpregnancy interval

The PRISM trial: Progesterone therapy does not alter birth outcomes in women with early pregnancy bleeding

High rates of over-diagnosis of pulmonary embolism by CT angiography

Patent foramen ovale associated with four-fold increased risk for ischemic stroke in patients with pulmonary embolism

Remote patient monitoring did not reduce heart failure readmissions: The BEAT-HF trial

Mavacamten shows promise for treating patients with obstructive hypertrophic cardiomyopathy

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force
  • RSVpreF vaccine prevents symptomatic respiratory syncytial virus infection
  • Incidence of Kawasaki disease found to be lower during the COVID-19 pandemic in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.